Skip to content

Dr. Oddone Francesco

Ophthalmologist, Researcher
Head of the Glaucoma Research Unit, Head of the Glaucoma Operative Unit (UOS) and Hospital-Territory Integration
Dr. Oddone Francesco
Research line: Research Line of Glaucoma and anterior segment with ocular annexes
Research unit: RU Glaucoma
Simple Operating Unit: Simple Operating Unit Glaucoma and Hospital-Territory Integration 
Specialization: Ophthalmology
Professional register: Registered with the Provincial Register of Surgeons and Physicians of Rome (Rome Provincial Order), Registration No. 50841, dated July 3, 2001.

Practices at IRCCS Fondazione G.B. Bietti, in the facilities of Via Livenza, 3 and Via di Santo Stefano Rotondo, 6, at the Presidio Ospedaliero Britannico, Rome.

Scientific Publications: PubMed

LinkedIn Profile: Francesco Oddone

 

  • 2008: Ph.D. in Advanced Technologies in Biomedicine from the University of Rome Tor Vergata, with a thesis on the Genetic Variability of Pigmentary Glaucoma.
  • 2004: Specialization in Ophthalmology with 110 cum laude (highest honors) from the University of Rome Tor Vergata.
  • 2000: Degree in Medicine and Surgery from the University of Rome Tor Vergata.
  • 2017 – Present: Member of the Grants Office at IRCCS Fondazione G.B. Bietti, Rome.
  • 2017 – Present: Head of the Inpatient Ward Operative Unit (UOS Area Degenze) at IRCCS Fondazione G.B. Bietti, Rome.
  • 2016 – Present: Head of the Glaucoma and Anterior Segment Research Line at IRCCS Fondazione G.B. Bietti, Rome.
  • 2014 – Present: Head of the Glaucoma Research Operative Unit at IRCCS Fondazione G.B. Bietti, Rome.
  • 2015 – Present: Hired with a full-time permanent contract with the qualification “Senior Medical Executive/Assistant Director” at IRCCS Fondazione G.B. Bietti, Rome.
  • 2008 – 2014: Coordinated and Continuous Collaboration Contract as a Level I Medical Director with the San Giovanni Addolorata Hospital (Rome), as part of its agreement with the IRCCS Fondazione G.B. Bietti, aimed at the project “Development and evaluation of the effectiveness of diagnostic-therapeutic pathways for macular diseases.”
  • 2004 – 2014: Medical Researcher with a collaboration contract within the Glaucoma Operative Unit, IRCCS Fondazione G.B. Bietti, Rome.
  • Lecturer at the School of Specialization in Ophthalmology, University of Rome Tor Vergata, teaching Evidence-Based Medicine in Ophthalmology.
  • Member of the “Next Generation Partnership” Special Interest Group of the European Glaucoma Society.
  • Member of the Program Planning Committee of the European Glaucoma Society.
  • Member of the Glaucoma Expert Committee of EVICR.net.
  • Member of the Data Safety Monitoring Board for the international Phase III clinical trial, Columbus AMD Study.
  • Member of the Italian Ophthalmological Society (SOI)
  • Member of the Italian Association for Glaucoma Study (AISG)
  • Member of the European Glaucoma Society (EGS)
  • Principal Investigator: A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic Solution in subjects with elevated intraocular pressure (MERCURY 3).
  • Principal Investigator: A phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort® eye drops (bimatoprost 0.03%/timolol 0.5%) to Taptiqom® eye drops (tafluprost 0.0015%/timolol 0.5%).
  • Principal Investigator: Clinical performance of Compass in the diagnosis of glaucoma: a comparison with HFA (CMP_002).
  • Principal Investigator: Evaluating the efficacy, safety, and tolerability of Bimatoprost 0.01% (BIMMD) and Tafluprost unit-dose 15 µg/ml (TUDPF) (SAFLUTAN) in patients with glaucoma or ocular hypertension suitable for prostaglandin therapy: A 6-month, European multicenter, randomized, cross-over, single-masked, investigator-masked study. (SPORT II)
  • Principal Investigator: Safety and efficacy with Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV).
  • Principal Investigator: XEN GLAUCOMA TREATMENT REGISTER (XEN-GTR): Italian multicenter prospective observational study.
  • Principal Investigator: Efficacy of an ophthalmic solution based on taurine and hyaluronic acid in glaucomatous and ocular hypertensive patients undergoing chronic treatment with ocular hypotensive drugs (OFTAL PLUS).
  • Principal Investigator: Preservative-free fixed-dose combination of tafluprost 0.0015% / timolol 0.5% in patients with open-angle glaucoma or ocular hypertension: clinical efficacy, tolerability, and safety in a real-world setting. (0240-0024) LOYADA.
  • Principal Investigator: Evaluation of BDNF and NGF levels in the plasma and tears of patients with glaucoma.
  • Comparison of the incidence and severity of conjunctival hyperemia associated with the topical use of bimatoprost 0.01% and latanoprost 0.005% in glaucomatous or ocular hypertensive patients.
  • Comparison of the effects of Bimatoprost 0.01% and Timolol 0.5% on circadian intraocular pressure.
  • Principal Investigator: Proteomic study of the sclero-corneal trabecular meshwork in glaucoma.
  • Principal Investigator: Intraocular pressure and tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or Preservative Free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in patients with Ocular hypertension or glaucoma: A Randomized, single-masked, 3-month cross-over, Investigator-led, European multicenter Trial (SPORT).
  • Principal Investigator: Efficacy of an ophthalmic solution based on cyanocobalamin, taurine, and hyaluronic acid in patients undergoing therapy with ocular hypotensive drugs.
  • Principal Investigator: Diagnostic Accuracy of the Heidelberg Retinal Tomograph 3.
  • Principal Investigator: Multicenter study on age-related corneal biomechanical changes.
  • Principal Investigator: Comparison between the Moorfields Multi Location Motion Displacement Test (MDT) and conventional perimetry in healthy and glaucomatous eyes.
  • Principal Investigator: Study of the epidemiology of glaucomatous disease in the urban population of Rome.
  • Principal Investigator: Change in the morphological and functional patterns of the ocular surface in patients treated with latanoprost after the use of TSP 0.5% preservative-free eye drops. Randomized, prospective, single-masked, multicenter study.
  • Comparison of the intraocular pressure-lowering effect of the fixed bimatoprost-timolol combination versus fixed carbonic anhydrase inhibitor-timolol combinations in patients with glaucoma or ocular hypertension uncontrolled by monotherapy: a retrospective study.
  • Influence of pupillary dilation on measurements of the Retinal Nerve Fiber Layer (RNFL), Optic Nerve Head (ONH), and Ganglion Cell Complex (GCC) using Spectral Domain Optical Coherence Tomography (OCT) (RTVue-100).
  • Learning effect of HEP (Heidelberg Edge Perimeter) perimetry in patients with ocular hypertension.
  • Prot. no. 006-02-Prospective longitudinal study for the evaluation of ocular surface disease development. Comparison between Treatment-Naive patients (who have not received specific treatments) with ocular hypertension or glaucoma versus patients without elevated ocular pressure. (SAHARA).

     

  • Evaluation of the genetic characteristics of pigment dispersion syndrome and pigmentary glaucoma, as well as other forms of glaucoma.

     

  • A 2×3-month, single-blind, multicenter clinical study comparing Ganfort and Duotrav in lowering intraocular pressure in patients with Pseudoexfoliation Glaucoma or Primary Open-Angle Glaucoma, previously treated with Xalacom.
  • Reproducibility and accuracy of the Cirrus-OCT.
  • Retrospective European study on the rate of progression of open-angle glaucoma.
  • A 3-month, single-blind, multicenter pilot study to evaluate the efficacy and safety of the fixed bimatoprost/timolol combination vs. latanoprost in previously untreated open-angle glaucoma patients at high risk of disease progression.
  • Learning effect of SITA-SWAP (Swedish Interactive Threshold Algorithm Short-Wavelength) perimetry in patients with ocular hypertension.
  • Ophthalmology,
  • Investigative Ophthalmology and Visual Science,
  • Archives of Ophthalmology,
  • Acta Ophthalmologica,
  • Journal of Glaucoma,
  • Eye,
  • European Journal Ophthalmology,
  • BMC Ophthalmology,
  • Graefe’s Archives of Ophthalmology,
  • Plos One,
  • BMJ Open,
  • American Journal of Ophthalmology
  • Member of the Advisory Board of the journal Advances in Therapy.
  • Member of the Scientific Board of the journal Italian Review of Ophthalmology.
  • Member of the Editorial Board of the journal Ophthalmology Point of Care.

Award for the Best Scientific Presentation conferred by the Italian Association for Glaucoma Study (AISG) in 2009for the presentation “The Genetic variability of pigmentary glaucoma.”

  • Organization and participation in a humanitarian mission in collaboration with Missioni Consolata Onlus during August 2014 for a duration of 14 days at the Wamba Catholic Hospital located in the village of Wamba (Kenya), aimed at the diagnosis and medical and surgical treatment of the main causes of blindness.
  • Organization and participation in a humanitarian mission in collaboration with Missioni Consolata Onlus during August 2013 for a duration of 14 days at the Wamba Catholic Hospital located in the village of Wamba (Kenya), aimed at the diagnosis and medical and surgical treatment of the main causes of blindness.
  • Organization and participation in a humanitarian mission from 05/14/2013 to 05/28/2013 in the city of Huambo (Angola) in collaboration with Unasolavita-Onlus, aimed at the diagnosis and medical and surgical treatment of the main causes of blindness.
Skip to content